Item Type | Name |
Academic Article
|
Cutting edge: induction of the antigen-processing enzyme IFN-gamma-inducible lysosomal thiol reductase in melanoma cells Is STAT1-dependent but CIITA-independent.
|
Academic Article
|
New insights in antigen processing and epitope selection: development of novel immunotherapeutic strategies for cancer, autoimmunity and infectious diseases.
|
Academic Article
|
HLA class II antigen presentation by prostate cancer cells.
|
Academic Article
|
Invariant chain modulates HLA class II protein recycling and peptide presentation in nonprofessional antigen presenting cells.
|
Academic Article
|
Gamma-IFN-inducible-lysosomal thiol reductase modulates acidic proteases and HLA class II antigen processing in melanoma.
|
Academic Article
|
Increased expression of B cell-associated regulatory cytokines by glatiramer acetate in mice with experimental autoimmune encephalomyelitis.
|
Academic Article
|
Augmentation of regulatory B cell activity in experimental allergic encephalomyelitis by glatiramer acetate.
|
Academic Article
|
HLA class II defects in Burkitt lymphoma: bryostatin-1-induced 17 kDa protein restores CD4+ T-cell recognition.
|
Academic Article
|
A possible cross-talk between autophagy and apoptosis in generating an immune response in melanoma.
|
Academic Article
|
CD80 binding polyproline helical peptide inhibits T cell activation.
|
Academic Article
|
Induction of apoptosis and immune response by all-trans retinoic acid plus interferon-gamma in human malignant glioblastoma T98G and U87MG cells.
|
Academic Article
|
Defects in HLA class II antigen presentation in B-cell lymphomas.
|
Academic Article
|
HLA-DM negatively regulates HLA-DR4-restricted collagen pathogenic peptide presentation and T cell recognition.
|
Academic Article
|
Downregulation of IL-17 and IL-6 in the central nervous system by glatiramer acetate in experimental autoimmune encephalomyelitis.
|
Academic Article
|
Insights into the Role of GILT in HLA Class II Antigen Processing and Presentation by Melanoma.
|
Academic Article
|
Molecular alterations in glioblastoma: potential targets for immunotherapy.
|
Academic Article
|
Mechanisms regulating enhanced human leukocyte antigen class II-mediated CD4 + T cell recognition of human B-cell lymphoma by resveratrol.
|
Academic Article
|
Enhancement of HLA class II-restricted CD4+ T cell recognition of human melanoma cells following treatment with bryostatin-1.
|
Concept
|
Receptors, Antigen, T-Cell
|
Concept
|
CD4 Antigens
|
Concept
|
Antigens, Differentiation
|
Concept
|
CD5 Antigens
|
Concept
|
Antigens, Neoplasm
|
Concept
|
B7-1 Antigen
|
Concept
|
HLA-D Antigens
|
Concept
|
B7-2 Antigen
|
Concept
|
Antigens, CD
|
Concept
|
Antigen Presentation
|
Concept
|
Histocompatibility Antigens Class II
|
Concept
|
HLA-DR4 Antigen
|
Concept
|
Antigen-Presenting Cells
|
Concept
|
HLA Antigens
|
Concept
|
Antigens, CD19
|
Concept
|
Antigens, Differentiation, B-Lymphocyte
|
Concept
|
CD28 Antigens
|
Academic Article
|
Disruption of HLA class II antigen presentation in Burkitt lymphoma: implication of a 47,000 MW acid labile protein in CD4+ T-cell recognition.
|
Academic Article
|
Elevation of c-MYC disrupts HLA class II-mediated immune recognition of human B cell tumors.
|
Academic Article
|
HLA Class II Antigen Presentation in Prostate Cancer Cells: A Novel Approach to Prostate Tumor Immunotherapy.
|
Academic Article
|
Multiple Defects Impair the HLA Class II Antigen Presentation Capacity of Burkitt Lymphoma.
|
Academic Article
|
Alteration of CD39+Foxp3+ CD4 T cell and cytokine levels in EAE/MS following anti-CD52 treatment.
|
Academic Article
|
Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy.
|
Academic Article
|
Inhibition of acid ceramidase regulates MHC class II antigen presentation and suppression of autoimmune arthritis.
|
Concept
|
CTLA-4 Antigen
|
Concept
|
CD52 Antigen
|
Academic Article
|
GILT Expression in Human Melanoma Cells Enhances Generation of Antigenic Peptides for HLA Class II-Mediated Immune Recognition.
|